Business UpdateJun 3, 2026, 06:06 AM
Mesa Laboratories Inc. 2026 Form 10-K Business Update
AI Summary
Mesa Laboratories Inc. filed its annual report on Form 10-K, detailing its business operations across four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The report highlights the recent acquisition of GKE, which has been integrated into the Sterilization and Disinfection Control division. The company also provided updates on its backlog, customer concentration, and human capital, noting a decrease in backlog and a stable employee headcount with reduced turnover.
Key Highlights
- Mesa Laboratories Inc. operates in four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics.
- The company acquired GKE GmbH, SAL GmbH, and GKE China in late 2023, integrating GKE into the Sterilization and Disinfection Control division.
- Backlog decreased to $33.6 million as of March 31, 2026, from $43.2 million in the prior year, primarily due to order timing in Clinical Genomics.
- No single customer accounted for more than 10% of consolidated revenues in fiscal year 2026, though one customer represented approximately 20% of the Clinical Genomics division's revenues.
- The company employed 717 individuals as of March 31, 2026, with a decrease in voluntary employee turnover compared to the previous fiscal year.
Price Impact
More from MLAB